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ABSTRACT
Background
The European Society of Cardiology and the European 
Society of Hypertension define hypertension as systolic 
blood pressure ≥140 mmHg Hg, or diastolic blood 
pressure ≥90 mmHg Hg, or both. Hypertension is a 
challenging condition in view of it being asymptomatic, 
highly prevalent and requiring continuous follow-up by 
the family physician.
Objective
To implement the available guidelines into clinical 
practice for better patient health.
Method
Multiple databases were used to perform the literature 
search including PubMed, National Institute of Clinical 
Excellence, Scottish Intercollegiate Guidelines Network, 
and the Turning Research Into Practice database. The 
following keywords were applied: hypertension, blood 
pressure, and primary care.
Results
Blood pressure needs to be measured by a device which 
is regularly calibrated. This could be a traditional mercury 
sphygmomanometer, aneroid sphygmomanometer or the 
automated sphygmomanometer. The cuff size should be 
adjusted according to the patient’s arm circumference 
and the patient should be seated comfortably with the 
arm rested such that the cuff is at the same level as the 
heart. During the initial assessment, the blood pressure 
should be measured in both arms and then the arm with 
the highest reading is used for subsequent measurements. 
Ambulatory blood pressure monitoring should be offered 
if the blood pressure is found to be over 140/90mmHg 
(measured at least twice) during the initial assessment.
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Conclusion
Appropriate management of hypertension will contribute 
significantly towards an improvement in overall patient 
health.
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INTRODUCTION
In the latest guidelines issued by the European Society 
of Cardiology (ESC) and the European Society of 
Hypertension (ESH), hypertension is defined as office 
systolic blood pressure values ≥140 mmHg and/or 
diastolic BP (DBP) values ≥90 mmHg (Williams, et al., 
2018). The incidence of hypertension increases with 
age and Afro-Caribbeans have a higher prevalence of 
hypertension as shown by various epidemiological 
studies (Burt, et al., 1995). Hypertension is a challenging 
condition since it is often asymptomatic, its prevalence 
is very high and requires continuous follow-up by the 
family physician. Hence, cardiovascular risk assessments 
(Franklin, et al., 2005) are very useful for primary 
prevention particularly in asymptomatic patients in the 
general population. The aim of this article is to be able to 
implement the available guidelines into clinical practice 
for better patient health.
METHOD
The searches were performed during the month of August 
2018 using multiple databases including PubMed, 
National Institute of Clinical Excellence (NICE), Scottish 
Intercollegiate Guidelines Network (SIGN), and the 
TRIP (Turning Research Into Practice) database. The 
MeSH (Medical Subject Headings) terms applied were: 
hypertension, blood pressure, and primary care.  The 
following search parameters were used for the literature 
search:
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•	 Scope:	management	of	hypertension.
•	 Population:	adults.
•	 Exclusions:	none.
RESULTS
Blood pressure  can be measured us ing the 
t r a d i t i o n a l  m e r c u r y  s p h y g m o m a n o m e t e r, 
aneroid sphygmomanometer or the automated 
sphygmomanometer which is becoming increasingly 
popular. Guidelines issued by the British Hypertension 
Society (BHS) in 2017 and the National Institute for 
Health and Clinical Excellence in 2016 recommend 
that every device should be regularly calibrated. The cuff 
size used should be adjusted according to the patient’s 
arm circumference. If the cuff size is too small, blood 
pressure may be overestimated whereas if it is too large, 
there may be an underestimation. The patient should 
be seated comfortably with the arm rested such that the 
cuff is at the same level as the heart. During the initial 
assessment, one should measure the blood pressure in 
both arms and then use the arm with the highest reading 
for subsequent measurements. A difference of up to 10 
mmHg is acceptable. However, if there is a difference of 
20 mm Hg or more in systolic blood pressure between the 
two arms, the physician should suggest that the patient be 
investigated for peripheral vascular disease (Clark, 2001).
If the blood pressure is found to be over 140/90mmHg 
(measured at least twice) during the initial assessment, 
one should offer 24-hour ambulatory blood pressure 
monitoring (ABPM) and home blood pressure monitoring 
(HBPM) if ABPM is not tolerated (Figure 1). One should 
also consider the possibility of white-coat hypertension 
in patients who are noted to be anxious when a clinician 
is measuring their blood pressure. For such patients, 
ABPM or HBPM should also be considered. When the 
blood pressure is found to be ≥180/110 mmHg (even 
when repeated a second time with the patient resting for 
five minutes), in the absence of any signs of malignant 
hypertension, antihypertensive treatment should be 
started straight away and the patient is reviewed regularly 
until the blood pressure is controlled (NICE, 2016.)
The National Institute for Health and Clinical 
Excellence, in the latest guidelines on the clinical 
management of primary hypertension in adults (last 
updated in 2016) recommends that patients should be 
referred to specialist care the same day in the presence 
of accelerated hypertension (i.e. blood pressure usually 
higher than 180/110 mmHg) with papilloedema and/
Figure 1: Hypertension care pathway (Physicians’ Academy for Cardiovascular Education, 2018)
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or fundal haemorrhages and exudates on fundoscopy 
(signs of malignant hypertension) or signs/symptoms 
of phaeochromocytoma such as abdominal pain, 
constipation, chest pain, dizziness, facial flushing and 
tachypnoea (NICE, 2016).
DISCUSSION
A patient with isolated diastolic hypertension (IDH) has a 
blood pressure persistently over 90mmHg with a normal 
systolic blood pressure. Data from the Framingham 
Heart Study showed that patients with isolated diastolic 
hypertension are 23.1 times more likely to develop 
systolic hypertension than those with normal diastolic 
blood pressure. Hence, it is recommended that patients 
with IDH should be followed up and a cardiovascular 
risk assessment is carried out.
Patients with significant postural hypotension (a drop 
in systolic blood pressure of at least 20 mmHg when 
standing up from a lying or sitting position) should be 
considered for a routine referral to hospital. Postural 
hypotension is commoner in the elderly, diabetic patients 
and those experiencing dizziness or recurrent falls (NICE, 
2016).
It is recommended by the Scottish Intercollegiate 
Guidelines Network that a cardiovascular risk assessment 
should be carried out every five years for all adults older 
than 40 years and for all those who have a first-degree 
relative who has developed cardiovascular disease when 
younger than 60 years of age (Franklin, et al., 2005).
Patients diagnosed with hypertension should be 
specifically asked regarding chest pain, shortness of 
breath, ankle swelling and palpitations which might 
suggest congestive heart failure or other complications 
of hypertension. Secondary hypertension should be 
considered in patients who are younger than 30 years, 
respond poorly to antihypertensives or who experience 
a sudden deterioration of their hypertension. Causes of 
secondary hypertension include diabetic nephropathy, 
obesity, polycystic kidney disease, renovascular pathology, 
Cushing syndrome, aldosteronism, phaeochromocytoma, 
hypo/hyperthyroidism and hyperparathyroidism 
(Williams, et al., 2018).
When examining patients diagnosed with 
hypertension, one should look specifically for signs of 
hypertensive complications. Auscultation of the heart 
and lungs should be carried out looking for murmurs 
and basal crepitations respectively which may indicate 
heart failure. The location of the apex beat should be 
assessed since hypertension can lead to left ventricular 
hypertrophy which in turn leads to a displaced apex 
beat. One should also assess for ankle/sacral oedema 
and carry out fundoscopy, looking for papilloedema or 
retinal haemorrhages (Williams, et al., 2018).
The following clinical investigations should be 
considered in patients who are diagnosed with 
hypertension in order to assess for complications of 
hypertension or for causes of secondary hypertension:
•	 Blood	 tests	 including	 renal	 profile,	 fasting	 blood	
glucose, lipid profile and thyroid function tests;
•	 12-lead	 electrocardiogram	 (ECG)	 looking	 for	 left	
ventricular hypertrophy, myocardial ischaemia or 
arrhythmias;
•	 Urinalysis	 to	 test	 for	 proteinuria	 or	 haematuria	 as	
possible markers of glomerular disease (Williams, et 
al., 2018).
Establishing the total risk of  
cardiovascular disease
It is recommended in current guidelines (SIGN, 2017) 
that one uses the Joint British Societies Cardiac Risk 
Assessor or the ASSIGN cardiovascular risk assessment 
tool to estimate cardiovascular risk in hypertensive 
patients (Williams, 2007).
Managing hypertension in the clinic
If the blood pressure is <150/95mmHg, the patient 
should be counselled regarding lifestyle modifications 
and the blood pressure should be reviewed at least 
annually. Evidence from the Trials of Hypertension 
Prevention, phase 1 (TOHP-1), showed that a weight 
loss of 10kg led to an average decrease in systolic blood 
pressure of 5-10mmHg (He, et al., 2000). A meta- analysis 
carried out by Whelton et al. (2002) found that regular 
aerobic exercise can reduce systolic blood pressure by 
3.8mmHg and diastolic blood pressure by 2.6mmHg in 
previously sedentary adults. Hypertensive patients (both 
males and females) should be advised not to exceed the 
limit of 14 units of alcohol per week. Findings from 
The Dietary Approaches to Stop Hypertension (DASH) 
trial demonstrate that there was a 5.5mmHg decrease 
in systolic blood pressure and a 3.0mmHg decrease 
in diastolic blood pressure when subjects were given a 
diet rich in fruits, vegetables and low-fat dairy products 
as opposed to subjects on a control diet, based on the 
typical American diet (Appel, et al., 1997).
For patients with a blood pressure ≥135/85 and 
a 10-year cardiovascular risk of more than 20%, 
antihypertensive treatment should be initiated along 
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with lifestyle changes. Based on evidence from the Anglo-
Scandinavian Cardiac Outcomes (ASCOT) trial (Sever, 
et al., 2003) and the NICE guidelines (2016), a four-
step algorithm is used to guide clinicians when treating 
patients with hypertension (Figure 2). The final decision 
on which drug to use will depend on the individual 
patient’s characteristics.
Step 1: In patients less than 55 years of age who 
are not of Afro-Caribbean descent, an angiotensin-
converting-enzyme (ACE) inhibitor is the first-line drug 
of choice. This can be substituted by an angiotensin 
receptor blocker (ARB) in patients who do not tolerate 
ACE inhibitors. For all Afro-Caribbean patients and 
Caucasians older than 55 years, a calcium channel 
blocker is recommended.
Step 2: A calcium channel blocker should be added 
for Caucasians younger than 55 years of age if the blood 
pressure is not controlled by an ACE inhibitor or ARB 
alone. An ACE inhibitor (or ARB if ACE inhibitor is not 
tolerated) should be added in all Afro-Caribbean patients 
and in Caucasians older than 55 years who still have 
high blood pressure despite calcium channel blockers.
Step 3: For all patients whose blood pressure is still 
not controlled, a thiazide-like diuretic should be added.
Step 4: If the blood pressure is not controlled with 
three drugs, one should consider adding a non-thiazide 
diuretic (e.g. furosemide or spironolactone), an alpha 
blocker (e.g. prazosin), or a beta blocker (e.g. atenolol). 
The primary care physician should also consider 
specialist opinion or refer the patient to secondary care.
Prescribing antihypertensive treatment
The physician should take into account the 
contraindications and side-effects of antihypertensive 
medications before prescribing. For instance, thiazide 
diuretics can cause gout and are contraindicated in 
refractory gout. ACE inibitors can cause renal impairment 
and are contraindicated in renal failure with creatinine 
>200 µmol/l, known renal artery stenosis, severe aortic 
stenosis and women of child-bearing age. At initiation of 
an ACE inhibitor or an angiotension receptor blocker, a 
renal profile including Glomerular Filtration Rate (GFR) 
should	be	taken	to	establish	a	“baseline”	level.	The	2012	
Kidney Disease Outcomes Quality Initiative (KDOQI) 
Clinical Practice Guidelines recommend that follow-up 
measurements should be carried out in around 4-12 week 
if the GFR ≥60 mL/min/1.73 m2, change in GFR is <15% 
and serum potassium ≤4.5 mEq/L (KDOQI, 2012).
Evidence for early intensive treatment
In the ACCELERATE (Aliskiren and the calcium channel 
blocker amlodipine combination as an initial treatment 
strategy for hypertension control) study, subjects who 
were randomised to the less effective of two treatments 
remained at a disadvantage when compared to the 
dual therapy group, even though the second agent was 
then added later on in the study (Brown, et al., 2011). 
Posthoc analysis of the Systolic Hypertension in Europe 
trial (Thijs, et al., 2010) also demonstrated reductions 
in blood pressure and in cardiovascular events for 
initial dual therapy when compared to monotherapy. 
Results from a recent retrospective cohort study carried 
out by Xu et al, (2015) showed that delaying the 
intensification of treatment by more than 1.4 months 
after elevation of systolic blood pressure was associated 
with increased cardiovascular morbidity and mortality, 
hence emphasising the importance of timely management 
and follow-up of hypertensive patients.
Figure 2: Four-step algorithm used to guide clinicians when treating patients with hypertension 
(Northern Ireland Formulary, 2015)
Step Age <55 years Age >55 years and black people  of African/Carribean descent of any age
1 A C
2 A + C
3 A + C + D
4
Resistant hypertension
A+ C +D + additional diuretic or alpha-blocker or beta-blocker
Consider seeking specialist advice
A =  ACE inhibitor or low cost ARB
C =  calcium-channel blocker
D =  thiazide-like diuretic
26  VOLUME 7 ISSUE 2 DECEMBER 2018 The Journal of the Malta College of Family Doctors 
Evidence against early intensive treatment
The PATHWAY-1 study was a randomised double-blind 
controlled trial which compared initial monotherapy 
with dual therapy in the management of hypertension 
(MacDonald, et al., 2015). At one year, the reduction 
in target organ damage (measured by reductions in left 
ventricular mass) was similar between the monotherapy 
and dual therapy groups.
Patient-centred approach
An observational study carried out by Little et al. in 
2001 found that patient satisfaction is higher if there is 
a mutually agreed plan and if patients are involved in the 
decision-making process. A systematic review carried out 
in 2012 concluded that clinicians must explore better 
patients’ ideas and concerns on drug side-effects in order 
to improve adherence to treatment (Marshall, Wolfe and 
McKevitt, 2012).
CONCLUSION
Hypertension is a very important condition encountered in 
primary care. Appropriate management of hypertension, 
making use of evidence-based recommendations as 
outlined above, will contribute significantly towards an 
improvement in overall patient health.
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